Skip to main content
Top
Published in: Endocrine 2/2016

01-11-2016 | Original Article

Changes of serum sclerostin and Dickkopf-1 levels during the menstrual cycle. A pilot study

Authors: Chrysoula G. Liakou, George Mastorakos, Konstantinos Makris, Ioannis G. Fatouros, Alexandra Avloniti, Helen Marketos, Julia D. Antoniou, Antonios Galanos, Ismene Dontas, Demetrios Rizos, Symeon Tournis

Published in: Endocrine | Issue 2/2016

Login to get access

Abstract

Studies in postmenopausal women have identified sclerostin as a strong candidate for mediating estrogen effects on the skeleton. The effects of estradiol on sclerostin and Dickkopf-1 in younger women remain unclear. The main purpose of this study is to investigate the impact of estradiol and gonadotrophins fluctuations during the menstrual cycle on circulating sclerostin and Dickkopf-1 levels and the possible relationship of sclerostin and Dickkopf-1 with changes in N-terminal propeptide of type 1 collagen and C-telopeptide of collagen cross-links. Fourteen healthy premenopausal Caucasian women, with regular menses, aged 33.6 ± 4.5 years participated. After the first day of menstruation and every-other-day up to the next menses, fasting serum estradiol, luteinizing hormone, follicle-stimulating hormone, sclerostin, Dickkopf-1, N-terminal propeptide of type 1 collagen, and C-telopeptide of collagen cross-links levels were measured in peripheral blood. Participants completed dietary questionnaires and the International physical activity questionnaire during the cycle. Neither sclerostin nor Dickkopf-1 levels changed significantly across the menstrual cycle (p = 0.18 and p = 0.39, respectively), while N-terminal propeptide of type 1 collagen and C-telopeptide of collagen cross-links levels presented cyclic variation (p < 0.001 and p = 0.004, respectively). Baseline sclerostin (29.23 ± 10.62 pmol/L) positively correlated with N-terminal propeptide of type 1 collagen (r = 0.71, p < 0.01) and C-telopeptide of collagen cross-links (r = 0.63, p < 0.05), while Dickkopf-1 (4.82 ± 2.23 pmol/L) correlated positively with N-terminal propeptide of type 1 collagen (r = 0.56, p < 0.05). Mid-cycle E2 levels presented significant negative association with the percent decrease of C-telopeptide of collagen cross-links at all-time points during the luteal period (r = −0.60 to −0.68, p < 0.05–0.01). Circulating sclerostin and Dickkopf-1 levels do not change across the menstrual cycle and do not demonstrate any relationship with estradiol in premenopausal women. Further investigation is needed concerning the role of sclerostin and Dickkopf-1 on bone turnover in young estrogen-sufficient women.
Literature
1.
go back to reference K.E. Poole, R.L. van Bezooijen, N. Loveridge, H. Hamersma, S.E. Papapoulos, C.W. Lowik, J. Reeve, Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 19, 1842–1844 (2005)PubMed K.E. Poole, R.L. van Bezooijen, N. Loveridge, H. Hamersma, S.E. Papapoulos, C.W. Lowik, J. Reeve, Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 19, 1842–1844 (2005)PubMed
2.
go back to reference R. Baron, G. Rawadi, S. Roman-Roman, Wnt signaling: a key regulator of bone mass. Curr. Top. Dev. Biol. 76, 103–127 (2006)CrossRefPubMed R. Baron, G. Rawadi, S. Roman-Roman, Wnt signaling: a key regulator of bone mass. Curr. Top. Dev. Biol. 76, 103–127 (2006)CrossRefPubMed
3.
go back to reference R. Baron, G. Rawadi, Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148, 2635–2643 (2007)CrossRefPubMed R. Baron, G. Rawadi, Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148, 2635–2643 (2007)CrossRefPubMed
4.
go back to reference M.K. Sutherland, J.C. Geoghegan, C. Yu, E. Turcott, J.E. Skonier, D.G. Winkler, J.A. Latham, Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 35, 828–835 (2004)CrossRefPubMed M.K. Sutherland, J.C. Geoghegan, C. Yu, E. Turcott, J.E. Skonier, D.G. Winkler, J.A. Latham, Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 35, 828–835 (2004)CrossRefPubMed
5.
go back to reference W. Balemans, M. Ebeling, N. Patel, E. Van Hul, P. Olson, M. Dioszegi, C. Lacza, W. Wuyts, J. Van Den Ende, P. Willems, A.F. Paes-Alves, S. Hill, M. Bueno, F.J. Ramos, P. Tacconi, F.G. Dikkers, C. Stratakis, K. Lindpaintner, B. Vickery, D. Foernzler, W. Van Hul, Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. 10, 537–543 (2001)CrossRefPubMed W. Balemans, M. Ebeling, N. Patel, E. Van Hul, P. Olson, M. Dioszegi, C. Lacza, W. Wuyts, J. Van Den Ende, P. Willems, A.F. Paes-Alves, S. Hill, M. Bueno, F.J. Ramos, P. Tacconi, F.G. Dikkers, C. Stratakis, K. Lindpaintner, B. Vickery, D. Foernzler, W. Van Hul, Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. 10, 537–543 (2001)CrossRefPubMed
6.
go back to reference W. Balemans, N. Patel, M. Ebeling, E. Van Hul, W. Wuyts, C. Lacza, M. Dioszegi, F.G. Dikkers, P. Hildering, P.J. Willems, J.B. Verheij, K. Lindpaintner, B. Vickery, D. Foernzler, W. Van Hul, Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet. 39, 91–97 (2002)CrossRefPubMedPubMedCentral W. Balemans, N. Patel, M. Ebeling, E. Van Hul, W. Wuyts, C. Lacza, M. Dioszegi, F.G. Dikkers, P. Hildering, P.J. Willems, J.B. Verheij, K. Lindpaintner, B. Vickery, D. Foernzler, W. Van Hul, Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet. 39, 91–97 (2002)CrossRefPubMedPubMedCentral
7.
go back to reference D.G. Winkler, M.K. Sutherland, J.C. Geoghegan, C. Yu, T. Hayes, J.E. Skonier, D. Shpektor, M. Jonas, B.R. Kovacevich, K. Staehling-Hampton, M. Appleby, M.E. Brunkow, J.A. Latham, Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 22, 6267–6276 (2003)CrossRefPubMedPubMedCentral D.G. Winkler, M.K. Sutherland, J.C. Geoghegan, C. Yu, T. Hayes, J.E. Skonier, D. Shpektor, M. Jonas, B.R. Kovacevich, K. Staehling-Hampton, M. Appleby, M.E. Brunkow, J.A. Latham, Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 22, 6267–6276 (2003)CrossRefPubMedPubMedCentral
8.
go back to reference A.G. Robling, P.J. Niziolek, L.A. Baldridge, K.W. Condon, M.R. Allen, I. Alam, S.M. Mantila, J. Gluhak-Heinrich, T.M. Bellido, S.E. Harris, C.H. Turner, Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J. Biol. Chem. 283, 5866–5875 (2008)CrossRefPubMed A.G. Robling, P.J. Niziolek, L.A. Baldridge, K.W. Condon, M.R. Allen, I. Alam, S.M. Mantila, J. Gluhak-Heinrich, T.M. Bellido, S.E. Harris, C.H. Turner, Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J. Biol. Chem. 283, 5866–5875 (2008)CrossRefPubMed
9.
go back to reference F. Morvan, K. Boulukos, P. Clement-Lacroix, S. Roman Roman, I. Suc-Royer, B. Vayssiere, P. Ammann, P. Martin, S. Pinho, P. Pognonec, P. Mollat, C. Niehrs, R. Baron, G. Rawadi, Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J. Bone Miner. Res. 21, 934–945 (2006)CrossRefPubMed F. Morvan, K. Boulukos, P. Clement-Lacroix, S. Roman Roman, I. Suc-Royer, B. Vayssiere, P. Ammann, P. Martin, S. Pinho, P. Pognonec, P. Mollat, C. Niehrs, R. Baron, G. Rawadi, Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J. Bone Miner. Res. 21, 934–945 (2006)CrossRefPubMed
10.
go back to reference J. Li, I. Sarosi, R.C. Cattley, J. Pretorius, F. Asuncion, M. Grisanti, S. Morony, S. Adamu, Z. Geng, W. Qiu, P. Kostenuik, D.L. Lacey, W.S. Simonet, B. Bolon, X. Qian, V. Shalhoub, M.S. Ominsky, H. Zhu Ke, X. Li, W.G. Richards, Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39, 754–766 (2006)CrossRefPubMed J. Li, I. Sarosi, R.C. Cattley, J. Pretorius, F. Asuncion, M. Grisanti, S. Morony, S. Adamu, Z. Geng, W. Qiu, P. Kostenuik, D.L. Lacey, W.S. Simonet, B. Bolon, X. Qian, V. Shalhoub, M.S. Ominsky, H. Zhu Ke, X. Li, W.G. Richards, Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39, 754–766 (2006)CrossRefPubMed
11.
go back to reference F.S. Wang, J.Y. Ko, C.L. Lin, H.L. Wu, H.J. Ke, P.J. Tai, Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats. Bone 40, 485–492 (2006)CrossRefPubMed F.S. Wang, J.Y. Ko, C.L. Lin, H.L. Wu, H.J. Ke, P.J. Tai, Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats. Bone 40, 485–492 (2006)CrossRefPubMed
12.
go back to reference G. Zaman, L.K. Saxon, A. Sunters, H. Hilton, P. Underhill, D. Williams, J.S. Price, L.E. Lanyon, Loading-related regulation of gene expression in bone in the contexts of estrogen deficiency, lack of estrogen receptor alpha and disuse. Bone 46, 628–642 (2010)CrossRefPubMedPubMedCentral G. Zaman, L.K. Saxon, A. Sunters, H. Hilton, P. Underhill, D. Williams, J.S. Price, L.E. Lanyon, Loading-related regulation of gene expression in bone in the contexts of estrogen deficiency, lack of estrogen receptor alpha and disuse. Bone 46, 628–642 (2010)CrossRefPubMedPubMedCentral
13.
go back to reference F.S. Mirza, I.D. Padhi, L.G. Raisz, J.A. Lorenzo, Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J. Clin. Endocrinol. Metab. 95, 1991–1997 (2010)CrossRefPubMedPubMedCentral F.S. Mirza, I.D. Padhi, L.G. Raisz, J.A. Lorenzo, Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J. Clin. Endocrinol. Metab. 95, 1991–1997 (2010)CrossRefPubMedPubMedCentral
14.
go back to reference Y.E. Chung, S.H. Lee, S.Y. Lee, S.Y. Kim, H.H. Kim, F.S. Mirza, S.K. Lee, J.A. Lorenzo, G.S. Kim, J.M. Koh, Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women. Osteoporos. Int. 23, 1235–1243 (2012)CrossRefPubMed Y.E. Chung, S.H. Lee, S.Y. Lee, S.Y. Kim, H.H. Kim, F.S. Mirza, S.K. Lee, J.A. Lorenzo, G.S. Kim, J.M. Koh, Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women. Osteoporos. Int. 23, 1235–1243 (2012)CrossRefPubMed
15.
go back to reference U.I. Mödder, J.A. Clowes, K. Hoey, J.M. Peterson, L. McCready, M.J. Oursler, B.L. Riggs, S. Khosla, Regulation of circulating sclerostin levels by sex steroids in women and in men. J. Bone Miner. Res. 26, 27–34 (2011)CrossRefPubMed U.I. Mödder, J.A. Clowes, K. Hoey, J.M. Peterson, L. McCready, M.J. Oursler, B.L. Riggs, S. Khosla, Regulation of circulating sclerostin levels by sex steroids in women and in men. J. Bone Miner. Res. 26, 27–34 (2011)CrossRefPubMed
16.
go back to reference S. Rinaldi, A. Geay, H. Déchaud, C. Biessy, A. Zeleniuch-Jacquotte, A. Akhmedkhanov, R.E. Shore, E. Riboli, P. Toniolo, R. Kaaks, Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiol. Biomarkers Prev. 11, 1065–1071 (2002)PubMed S. Rinaldi, A. Geay, H. Déchaud, C. Biessy, A. Zeleniuch-Jacquotte, A. Akhmedkhanov, R.E. Shore, E. Riboli, P. Toniolo, R. Kaaks, Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiol. Biomarkers Prev. 11, 1065–1071 (2002)PubMed
17.
go back to reference S. Tournis, E. Michopoulou, I.G. Fatouros, I. Paspati, M. Michalopoulou, P. Raptou, D. Leontsini, A. Avloniti, M. Krekoukia, V. Zouvelou, A. Galanos, N. Aggelousis, A. Kambas, I. Douroudos, G.P. Lyritis, K. Taxildaris, N. Pappaioannou, Effect of rhythmic gymnastics on volumetric bone mineral density and bone geometry in premenarcheal female athletes and controls. J. Clin. Endocrinol. Metab. 95, 2755–2762 (2010)CrossRefPubMed S. Tournis, E. Michopoulou, I.G. Fatouros, I. Paspati, M. Michalopoulou, P. Raptou, D. Leontsini, A. Avloniti, M. Krekoukia, V. Zouvelou, A. Galanos, N. Aggelousis, A. Kambas, I. Douroudos, G.P. Lyritis, K. Taxildaris, N. Pappaioannou, Effect of rhythmic gymnastics on volumetric bone mineral density and bone geometry in premenarcheal female athletes and controls. J. Clin. Endocrinol. Metab. 95, 2755–2762 (2010)CrossRefPubMed
18.
go back to reference M. Cidem, T.A. Usta, I. Karacan, S.H. Kucuk, M. Uludag, K. Gun, Effects of sex steroids on serum sclerostin levels during the menstrual cycle. Gynecol. Obstet. Invest. 75, 179–184 (2013)CrossRefPubMed M. Cidem, T.A. Usta, I. Karacan, S.H. Kucuk, M. Uludag, K. Gun, Effects of sex steroids on serum sclerostin levels during the menstrual cycle. Gynecol. Obstet. Invest. 75, 179–184 (2013)CrossRefPubMed
19.
go back to reference I. Gorai, Y. Taguchi, O. Chaki, R. Kikuchi, M. Nakayama, B.C. Yang, S. Yokota, H. Minaguchi, Serum soluble interleukin-6 receptor and biochemical markers of bone metabolism show significant variations during the menstrual cycle. J. Clin. Endocrinol. Metab. 83, 326–332 (1998)CrossRefPubMed I. Gorai, Y. Taguchi, O. Chaki, R. Kikuchi, M. Nakayama, B.C. Yang, S. Yokota, H. Minaguchi, Serum soluble interleukin-6 receptor and biochemical markers of bone metabolism show significant variations during the menstrual cycle. J. Clin. Endocrinol. Metab. 83, 326–332 (1998)CrossRefPubMed
20.
go back to reference K.M. Chiu, J. Ju, D. Mayes, P. Bacchetti, S. Weitz, C.D. Arnaud, Changes in bone resorption during the menstrual cycle. J. Bone Miner. Res. 4, 609–615 (1999)CrossRef K.M. Chiu, J. Ju, D. Mayes, P. Bacchetti, S. Weitz, C.D. Arnaud, Changes in bone resorption during the menstrual cycle. J. Bone Miner. Res. 4, 609–615 (1999)CrossRef
21.
go back to reference H.K. Nielsen, K. Brixen, R. Bouillon, L. Mosekilde, Changes in biochemical markers of osteoblastic activity during the menstrual cycle. J. Clin. Endocrinol. Metab. 70, 1431–1437 (1990)CrossRefPubMed H.K. Nielsen, K. Brixen, R. Bouillon, L. Mosekilde, Changes in biochemical markers of osteoblastic activity during the menstrual cycle. J. Clin. Endocrinol. Metab. 70, 1431–1437 (1990)CrossRefPubMed
22.
go back to reference I. Gorai, O. Chaki, M. Nakayama, H. Minaguchi, Urinary biochemical markers for bone resorption during the menstrual cycle. Calcif. Tissue Int. 57, 100–104 (1995)CrossRefPubMed I. Gorai, O. Chaki, M. Nakayama, H. Minaguchi, Urinary biochemical markers for bone resorption during the menstrual cycle. Calcif. Tissue Int. 57, 100–104 (1995)CrossRefPubMed
23.
go back to reference M.L. Gass, R. Kagan, J.D. Kohles, M.G. Martens, Bone turnover marker profile in relation to the menstrual cycle of premenopausal healthy women. Menopause 15, 667–675 (2008)CrossRefPubMed M.L. Gass, R. Kagan, J.D. Kohles, M.G. Martens, Bone turnover marker profile in relation to the menstrual cycle of premenopausal healthy women. Menopause 15, 667–675 (2008)CrossRefPubMed
24.
go back to reference B. Mozzanega, S. Gizzo, D. Bernardi, L. Salmaso, T.S. Patrelli, R. Mioni, L. Finos, G.B. Nardelli, Cyclic variations of bone resorption mediators and markers in the different phases of the menstrual cycle. J. Bone Miner. Metab. 31, 461–467 (2013)CrossRefPubMed B. Mozzanega, S. Gizzo, D. Bernardi, L. Salmaso, T.S. Patrelli, R. Mioni, L. Finos, G.B. Nardelli, Cyclic variations of bone resorption mediators and markers in the different phases of the menstrual cycle. J. Bone Miner. Metab. 31, 461–467 (2013)CrossRefPubMed
25.
go back to reference G. Lombardi, P. Lanteri, A. Colombini, G. Banfi, Blood biochemical markers of bone turnover: pre-analytical and technical aspects of sample collection and handling. Clin. Chem. Lab. Med. 50, 771–789 (2012)CrossRefPubMed G. Lombardi, P. Lanteri, A. Colombini, G. Banfi, Blood biochemical markers of bone turnover: pre-analytical and technical aspects of sample collection and handling. Clin. Chem. Lab. Med. 50, 771–789 (2012)CrossRefPubMed
26.
go back to reference G. Mabilleau, A. Mieczkowska, M.E. Edmonds, Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression. Diabet. Med. 27, 925–932 (2010)CrossRefPubMed G. Mabilleau, A. Mieczkowska, M.E. Edmonds, Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression. Diabet. Med. 27, 925–932 (2010)CrossRefPubMed
27.
go back to reference M.S. Ardawi, H.A. Al-Kadi, A.A. Rouzi, M.H. Qari, Determinants of serum sclerostin in healthy pre- and postmenopausal women. J. Bone Miner. Res. 26, 2812–2822 (2011)CrossRefPubMed M.S. Ardawi, H.A. Al-Kadi, A.A. Rouzi, M.H. Qari, Determinants of serum sclerostin in healthy pre- and postmenopausal women. J. Bone Miner. Res. 26, 2812–2822 (2011)CrossRefPubMed
28.
go back to reference U.I. Mödder, K.A. Hoey, S. Amin, L.K. McCready, S.J. Achenbach, B.L. Riggs, L.J. Melton III, S. Khosla, Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J. Bone Miner. Res. 26, 373–379 (2011)CrossRefPubMed U.I. Mödder, K.A. Hoey, S. Amin, L.K. McCready, S.J. Achenbach, B.L. Riggs, L.J. Melton III, S. Khosla, Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J. Bone Miner. Res. 26, 373–379 (2011)CrossRefPubMed
29.
go back to reference K. Amrein, S. Amrein, C. Drexler, H.P. Dimai, H. Dobnig, K. Pfeifer, A. Tomaschitz, T.R. Pieber, A. Fahrleitner-Pammer, Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J. Clin. Endocrinol. Metab. 97, 148–154 (2012)CrossRefPubMed K. Amrein, S. Amrein, C. Drexler, H.P. Dimai, H. Dobnig, K. Pfeifer, A. Tomaschitz, T.R. Pieber, A. Fahrleitner-Pammer, Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J. Clin. Endocrinol. Metab. 97, 148–154 (2012)CrossRefPubMed
30.
go back to reference C. Durosier, A. van Lierop, S. Ferrari, T. Chevalley, S. Papapoulos, R. Rizzoli, Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women. J. Clin. Endocrinol. Metab. 98, 3873–3883 (2013)CrossRefPubMed C. Durosier, A. van Lierop, S. Ferrari, T. Chevalley, S. Papapoulos, R. Rizzoli, Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women. J. Clin. Endocrinol. Metab. 98, 3873–3883 (2013)CrossRefPubMed
31.
go back to reference A.G. Costa, M.D. Walker, C.A. Zhang, S. Cremers, E. Dworakowski, D.J. McMahon, G. Liu, J.P. Bilezikian, Circulating sclerostin levels and markers of bone turnover in Chinese-American and white women. J. Clin. Endocrinol. Metab. 98, 4736–4743 (2013)CrossRefPubMedPubMedCentral A.G. Costa, M.D. Walker, C.A. Zhang, S. Cremers, E. Dworakowski, D.J. McMahon, G. Liu, J.P. Bilezikian, Circulating sclerostin levels and markers of bone turnover in Chinese-American and white women. J. Clin. Endocrinol. Metab. 98, 4736–4743 (2013)CrossRefPubMedPubMedCentral
33.
go back to reference G. Lombardi, P. Lanteri, A. Colombini, M. Mariotti, G. Banfi, Sclerostin concentrations in athletes: role of load and gender. J. Biol. Regul. Homeost. Agents. 26, 157–163 (2012)PubMed G. Lombardi, P. Lanteri, A. Colombini, M. Mariotti, G. Banfi, Sclerostin concentrations in athletes: role of load and gender. J. Biol. Regul. Homeost. Agents. 26, 157–163 (2012)PubMed
34.
go back to reference Z.A. Zhong, H. Sun WChen, H. Zhang, N.E. Lane, W. Yao, Inactivation of the progesterone receptor in Mx1+ cells potentiates osteogenesis in calvaria but not in long bone. PLoS One 10, e0139490 (2015)CrossRefPubMedPubMedCentral Z.A. Zhong, H. Sun WChen, H. Zhang, N.E. Lane, W. Yao, Inactivation of the progesterone receptor in Mx1+ cells potentiates osteogenesis in calvaria but not in long bone. PLoS One 10, e0139490 (2015)CrossRefPubMedPubMedCentral
35.
go back to reference J.H. Liu, K.N. Muse, The effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial. Am. J. Obstet. Gynecol. 192, 1316–1323 (2005)CrossRefPubMed J.H. Liu, K.N. Muse, The effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial. Am. J. Obstet. Gynecol. 192, 1316–1323 (2005)CrossRefPubMed
36.
go back to reference Z. Ikram, L. Dulipsingh, K.M. Prestwood, Lack of effect of short-term micronized progesterone on bone turnover in postmenopausal women. J. Womens Health Gend. Based Med. 7, 973–8 (1999)CrossRef Z. Ikram, L. Dulipsingh, K.M. Prestwood, Lack of effect of short-term micronized progesterone on bone turnover in postmenopausal women. J. Womens Health Gend. Based Med. 7, 973–8 (1999)CrossRef
37.
go back to reference G. Azizi, A. Hansen, K.M. Prestwood, Effect of micronized progesterone on bone turnover in postmenopausal women on estrogen replacement therapy. Endocr. Res. 29, 133–140 (2003)CrossRefPubMed G. Azizi, A. Hansen, K.M. Prestwood, Effect of micronized progesterone on bone turnover in postmenopausal women on estrogen replacement therapy. Endocr. Res. 29, 133–140 (2003)CrossRefPubMed
Metadata
Title
Changes of serum sclerostin and Dickkopf-1 levels during the menstrual cycle. A pilot study
Authors
Chrysoula G. Liakou
George Mastorakos
Konstantinos Makris
Ioannis G. Fatouros
Alexandra Avloniti
Helen Marketos
Julia D. Antoniou
Antonios Galanos
Ismene Dontas
Demetrios Rizos
Symeon Tournis
Publication date
01-11-2016
Publisher
Springer US
Published in
Endocrine / Issue 2/2016
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-1056-9

Other articles of this Issue 2/2016

Endocrine 2/2016 Go to the issue